Loading…
← CockpitCompetitor Analysis › 301211.SZ Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A301211.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 63
Mkt cap
$619M
US dollars, full cap
$/day
$12.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.4 pp
WACC 10.7%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥10.00
1D-1.5%
1W-8.8%
1M-12.9%
3M-15.7%
6M-10.0%
YTD-18.2%
1Y-29.1%
ATR %4.7%
52w lowhigh41.0% off high

What Hubei Biocause Heilen Pharmaceutical does

Employees: 987

Hubei Biocause Heilen Pharmaceutical at a glance

Size Hubei Biocause Heilen Pharmaceutical (301211.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $619M, the 3172nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.00 on 18 Nov 2026.

Performance Over six months the shares fell 10.0%, against -25.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 13.5% over the last twelve months (peer median +4.6%); the operating margin is 4.1% (peer median 4.4%).

Valuation It trades at 5.3× enterprise value to sales against a peer median of 3.0× (7th most expensive of 16).

Capital Return on invested capital runs 5.4 points below its cost of capital (10.7% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026301211.SZ 91Peer median 76
Six months, rebased to 100: Hubei Biocause Heilen Pharmaceutical against the median of its 20 peers (local-currency closes).

Hubei Biocause Heilen Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥489MCN¥451MCN¥445MCN¥659MCN¥513M
Revenue growth—+1%-33%+29%—
Gross profitCN¥148MCN¥90.9MCN¥122MCN¥257MCN¥142M
EBITDAn/aCN¥47.5MCN¥56.6MCN¥167MCN¥96.9M
Net incomeCN¥53.6MCN¥34.9MCN¥91.5MCN¥176MCN¥126M
Free cash flow-CN¥44.5M-CN¥29.0M-CN¥63.9M-CN¥49.5MCN¥175M
Capital expenditureCN¥64.4MCN¥52.3MCN¥164MCN¥187MCN¥76.0M
Total debtCN¥1.54MCN¥14.4MCN¥19.2MCN¥24.8MCN¥19.8M

Quarterly statements and history in the cockpit →

Hubei Biocause Heilen Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%OLMABCAX4105ORCHPHARMA300194002940603567002793185750ABUS300878DBV300233600976000566IMMX301211.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hubei Biocause Heilen Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×10×20×4105ORCHPHARMA300194603567185750ABUS3008783010964123000566301211.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hubei Biocause Heilen Pharmaceutical is the large dot.

Hubei Biocause Heilen Pharmaceutical competitors and peer comparison

How Hubei Biocause Heilen Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hubei Biocause Heilen Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure301211.SZPeer medianRank in peer set
1-month return-12.9%-10.7%5th lowest of 20
6-month return-10.0%-25.9%4th highest of 20
Distance from 52-week high-41.0%-39.9%10th lowest of 20
Revenue growth (TTM)+13.5%+4.6%5th highest of 16
Operating margin4.1%4.4%7th lowest of 15
EV / Sales5.3×3.0×7th most expensive of 16
ROIC minus cost of capital-5.4 pp-3.9 pp6th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a

Questions

Which companies are Hubei Biocause Heilen Pharmaceutical's closest peers?
The cockpit's peer set: Olema Pharmaceuticals (OLMA), Bicara Therapeutics (BCAX), TTY Biopharm (4105.TWO), Orchid Pharma (ORCHPHARMA.NS), Fuan Pharmaceutical (Group) (300194.SZ), Zhejiang Anglikang Pharmaceutical (002940.SZ), HeiLongJiang ZBD Pharmaceutical (603567.SS), Achieve Life Sciences (QUIT).
Is Hubei Biocause Heilen Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 5.3× against a peer median of 3.0×, 7th most expensive of 16 in its peer set.
How has Hubei Biocause Heilen Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -10.0% against -25.9% for the median peer; over one year -29.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.